Role of goserelin-depot in the clinical management of uterine fibroids.
On 30 women suffering from uterine fibroids, the monthly subcutaneous administration of goserelin depot (3.6 mg) for 6 (n = 22) or 12 months (n = 8) induced an about 50% shrinkage of uterus and fibroid volume, and within 3 months, an increase in the haematocrit value, with no metabolic side effects or detectable bone demineralization, evaluated by single photon absortiometry at distal radius. Both uterine and fibroid volumes reversed to pretreatment values after 3 months of goserelin depot withdrawal. In comparison with untreated subjects, on another 10 patients a three month administration of goserelin depot reduced the loss of blood during the surgical removal of the uterus or fibroids. Present data indicate that goserelin depot is effective and relatively safe in the medical management of uterine fibroids. Although, goserelin depot cannot yet be proposed as a definite medical therapy, it may represent a useful instrument in the presurgical management of uterine fibroids.
Cagnacci
A
A
Department of Obstetrics and Gynecology, University of Cagliari, Italy.
Paoletti
A M
AM
Soldani
R
R
Angiolucci
M
M
Arangino
S
S
Falqui
A
A
Melis
G B
GB
D000328:Adult; D016063:Blood Loss, Surgical / Q000517:prevention & control; D003692:Delayed-Action Preparations; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D007889:Leiomyoma / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000378:metabolism; D008875:Middle Aged; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000601:surgery
D003692:Delayed-Action Preparations; D008055:Lipids; D017273:Goserelin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone